scholarly journals Cystoid Macular Edema: Causes, Diagnosis and Treatment

2015 ◽  
Vol 3 (3) ◽  
pp. 131-139 ◽  
Author(s):  
Noelia Bravo-Alcobendas ◽  
Joseba Zulueta ◽  
Elena Salobrar-García ◽  
Juan J Salazar ◽  
José M Ramírez
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Retinal Thickness ◽  
Retinal Dystrophy ◽  
Standard Technique ◽  
Blood Retinal Barrier ◽  
Fluid Extravasation ◽  
Intraocular Tumors ◽  
Inflammatory Drugs

The purpose of this paper is to conduct a review of studies on cystoid macular edema published in the last seven years. Cystoid macular edema is a major cause of loss of visual acuity. It is the final common pathway of many diseases and can be caused by numerous processes including inflammatory, vascular, adverse drug reactions, retinal dystrophy or intraocular tumors. These processes disrupt the blood-retinal barrier, with fluid extravasation to the macular parenchyma. Imaging tests are essential for both detection and monitoring of this pathology. Fluorescein angiography and autofluorescence show the leakage of liquid from perifoveal vessels into the tissue where it forms cystic spaces. Optical coherence tomography is currently the gold standard technique for diagnosis and monitoring. This allows objective measurement of retinal thickness, which correlates with visual acuity and provides more complete morphological information. Based on the underlying etiology, the therapeutic approach can be either surgical or medical with anti-inflammatory drugs. We found that disruption of the blood-retinal barrier for various reasons is the key point in the pathogenesis of cystoid macular edema, therefore we believe that studies on its treatment should proceed on this path.

Cystoid Macular Edema Secondary to Paclitaxel Therapy

2019 ◽  
Vol 2 ◽  
pp. 1 ◽  
Author(s):  
Anibal Martin Folgar ◽  
Jorge Oscar Zarate
Keyword(s):  
Optical Coherence Tomography ◽  
Visual Acuity ◽  
Fluorescein Angiography ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Metastatic Breast ◽  
Breast Adenocarcinoma ◽  
Optical Coherence ◽  
Ophthalmoscopic Examination

We present a 57-year-old referred reduced visual acuity who was in treatment with paclitaxel for developing metastatic breast adenocarcinoma. Ophthalmoscopic examination, optical coherence tomography, and autofluorescence show the cystoid macular edema, but fluorescein angiography is normal, without leakage of dye in the late times. The patient responds well 8 weeks after stopping antineoplastic. Paclitaxel can cause cystoid macular edema and lifting a recovery both anatomical and functional of the macula.

scholarly journals Real-world outcomes of two-year Conbercept therapy for diabetic macular edema

2021 ◽  
Vol 14 (3) ◽  
pp. 416-422
Author(s):  
Yong Cheng ◽  
◽  
Ming-Wei Zhao ◽  
Tong Qian ◽  
◽  
...  
Keyword(s):  
Visual Acuity ◽  
Adverse Events ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Retinal Thickness ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
Number Of Injections ◽  
Best Corrected Visual Acuity

AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo. RESULTS: The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 μm) in comparison with the baseline (510.9±186.1 μm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 μm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted. CONCLUSION: IVC is safe and effective for the treatment of DME.

Subthreshold micropulse yellow laser for the management of refractory cystoid macular edema consequent to complicated cataract surgery

2020 ◽  
pp. 112067212092800
Author(s):  
Tommaso Verdina ◽  
Cecilia Ferrari ◽  
Edoardo Valerio ◽  
Alberto Brombin ◽  
Andrea Lazzerini ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Cataract Surgery ◽  
Macular Edema ◽  
Laser Treatment ◽  
Cystoid Macular Edema ◽  
Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Complicated Cataract ◽  
Yellow Laser ◽  
Best Corrected Visual Acuity

Purpose: To report the safety and efficacy of subthreshold micropulse yellow laser of 577 nm for a complex case of refractory pseudophakic cystoid macular edema. Methods: A retrospective chart review of an interventional case report of three subthreshold micropulse yellow laser interventions for refractory pseudophakic cystoid macular edema. Patient: A 77-year-old healthy female underwent pseudoexfoliative cataract surgery complicated by posterior capsule rupture and sulcus intraocular lens implantation. After 3 months, she required a scleral fixation of the same lens, due to a lack of capsular support and decentration of the intraocular lens. One month later, she experienced a severe pseudophakic cystoid macular edema (foveal thickness of 399 µm and best-corrected visual acuity of 20/80 Snellen). The condition was refractory to conventional treatments prior to subthreshold micropulse yellow laser interventions, including non-steroidal anti-inflammatory eye drops, topical steroids, oral indomethacin and three sub-Tenon’s triamcinolone injections, attempted over a 14-month period. Results: Subthreshold micropulse yellow laser treatment was performed and immediate resolution was achieved and maintained for 2 months. Two cases of edema relapse were observed at 3 months from initial laser treatment and again at 4 months from the second laser treatment. Final patient’s follow-up at 6 months from the third laser treatment evidenced the absence of edema, improved visual acuity (foveal thickness of 265 µm/best-corrected visual acuity of 20/30 Snellen) and the absence of complications. Conclusions: Subthreshold micropulse yellow laser seems to be a safe and effective treatment for short-term resolution of refractory pseudophakic cystoid macular edema after complicated cataract surgery and represents a useful alternative to expensive and invasive therapies. A trend towards a longer duration of edema resolution with every subthreshold micropulse yellow laser repetition was observed.

Diabetic Macular Edema

1998 ◽  
Vol 8 (3) ◽  
pp. 127-130 ◽  
Author(s):  
J. Cunha-Vaz
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Retinal Thickness ◽  
Vasogenic Edema ◽  
Retinal Disease ◽  
Retinal Edema ◽  
Blood Retinal Barrier ◽  
Retinal Tissue ◽  
First Case ◽  
Retinal Thickness Analyser

Retinal edema is defined as any increase of water in retinal tissue resulting in an increase in its volume. This increase may be initially intracellular or extracellular. In the first case, there is cytotoxic edema. In the second, vasogenic edema, directly associated with an alteration of the blood-retinal barrier (BRB). Retinal thickness can now be measured, using the retinal thickness analyser (RTA). Similarly, local breakdown of the BRB can now be mapped using the retinal leakage analyser (RLA). The application of these methods to diabetic macular edema has shown that both types of retinal retinopathy edema occur in the initial stages of diabetic retinal disease. These observations suggest a role for neuroprotective and vasoprotective agents in the management of diabetic retinal disease.

Ranibizumab for Persistent Diabetic Macular Edema after Bevacizumab Treatment

2016 ◽  
Vol 27 (2) ◽  
pp. 210-214 ◽  
Author(s):  
Gabriel Katz ◽  
Elad Moisseiev ◽  
Dafna Goldenberg ◽  
Joseph Moisseiev ◽  
Yosef Lomnicky ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Retinal Thickness ◽  
Significant Gain ◽  
Bevacizumab Treatment ◽  
The Mean ◽  
The Difference ◽  
Persistent Diabetic Macular Edema

Purpose To evaluate the efficacy of switching from bevacizumab to ranibizumab in patients with diabetic macular edema (DME). Methods This was a retrospective study of patients with DME initially treated with bevacizumab and switched to ranibizumab. Visual acuity (VA) and central retinal thickness (CRT) were retrieved at fixed timepoints prior to and after the switch. Results Forty eyes of 32 patients were included in the study. The difference in VA between any of these fixed timepoints was not statistically significant. A significant gain in VA was found in eyes that lost more than 0.1 logMAR during treatment with the last 3 bevacizumab injections. The mean CRT was significantly lower after the first 3 ranibizumab injections and at the final follow-up (p<0.001), a 67 ± 14 μm and 78 ± 18 μm reduction in thickness, respectively. Conclusions Switching to ranibizumab resulted in a significant decrease in the CRT of eyes with DME, and should be considered when there is a lack of response or deterioration while on bevacizumab injections. A significant gain in VA was observed in a subgroup of eyes that lost more than one line while receiving the last 3 bevacizumab injections prior to the switch.

Influence of Orthostasis and Daytime on Retinal Thickness in Uveitis-Associated Cystoid Macular Edema

2013 ◽  
Vol 39 (4) ◽  
pp. 395-402 ◽  
Author(s):  
Marion R. Munk ◽  
Christopher G. Kiss ◽  
Cem Ekmekcioglu ◽  
Wolfgang Huf ◽  
Florian Sulzbacher ◽  
...  
Keyword(s):  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Retinal Thickness

scholarly journals CHANGES IN VISUAL ACUITY AND FOVEAL PHOTORECEPTOR INTEGRITY IN EYES WITH CHRONIC CYSTOID MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION

Retina ◽  
2012 ◽  
Vol 32 (4) ◽  
pp. 792-798 ◽  
Author(s):  
Yumiko Kurashige ◽  
Akitaka Tsujikawa ◽  
Tomoaki Murakami ◽  
Kazuaki Miyamoto ◽  
Ken Ogino ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Cystoid Macular Edema ◽  
Vein Occlusion
Sign in / Sign up

Export Citation Format

Share Document